Philip Nickson

General Counsel at MONTE ROSA THERAPEUTICS, INC.

Net worth: 1 M $ as of 2026-05-30

47 year

Health Technology

Consumer Services

Profile

Philip Nickson is currently Chief Business & Legal Officer at Monte Rosa Therapeutics, Inc. since 2024.
Previously, Dr. Nickson was Vice President-Intellectual Property at Momenta Pharmaceuticals, Inc. from 2012 to 2021.
Education includes a doctorate from The University of Manchester and a graduate degree from Suffolk University.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
MONTE ROSA THERAPEUTICS, INC. 0.07%	2026-04-08	55,000 ( 0.07% )	1 M $	2026-05-30

Philip Nickson active positions

Companies	Position	Start
MONTE ROSA THERAPEUTICS, INC.	General Counsel	2021-02-28

All active positions of Philip Nickson

Former positions of Philip Nickson

Companies	Position	End
MOMENTA PHARMACEUTICALS, INC.	Corporate Officer/Principal	2021-02-28

See the detail of Philip Nickson's experience

Training of Philip Nickson

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Philip Nickson's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
Momenta Pharmaceuticals, Inc. Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that discovers and develops novel biologic therapies for the treatment of rare immune-mediated diseases	Health Technology
The University of Manchester The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Suffolk University Suffolk University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases	Health Technology